Key facts
- This page summarizes Robert Lorne Hopfner's Form 4 filing for Evommune, Inc..
- 14 reported transactions and 10 derivative rows are listed below.
- Accepted by SEC: 12 Nov 2025, 16:19.
Robert Lorne Hopfner - 07 Nov 2025 Form 4 Insider Report for Evommune, Inc.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- EVMN on NYSE
- Reported as of
- 07 Nov 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Nov 2025, 16:19:43 UTC
- Prior SEC filing
- 05 Nov 2025
- Next SEC filing
- 22 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gregory S. Moss, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Lorne Hopfner filed Form 4 for Evommune, Inc. on 12 Nov 2025.
Change
- Previous filing in this sequence was filed on 05 Nov 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001551966
Primary reporting owner
Hopfner Robert Lorne
- Relationship
- Director, 10%+ Owner
- Address
- C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO
- Signature
- /s/ Gregory S. Moss, Attorney-in-Fact
- Signature date
- 12 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EVMN
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +3,026
- Change %
- Price
- Shares after
- 3,026
- Date
- 07 Nov 2025
- Ownership
- By Trust
- Footnotes
- F1, F2
EVMN
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,441,032
- Change %
- Price
- Shares after
- 1,441,032
- Date
- 07 Nov 2025
- Ownership
- By NFLS Delta III Limited
- Footnotes
- F1, F3, F4, F5, F6
EVMN
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,632,441
- Change %
- Price
- Shares after
- 1,632,441
- Date
- 07 Nov 2025
- Ownership
- By Pivotal bioVenture Partners Fund I, L.P.
- Footnotes
- F1, F3, F4, F5, F7
EVMN
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +294,502
- Change %
- Price
- Shares after
- 294,502
- Date
- 07 Nov 2025
- Ownership
- By Pivotal bioVenture Partners Fund II, L.P.
- Footnotes
- F5, F8
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EVMN
transaction
Derivative
Series Seed Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -25,790
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- By Trust
- Underlying class
- Common Stock
- Underlying amount
- 3,026
- Exercise price
- Footnotes
- F1, F2
EVMN
transaction
Derivative
Series Seed Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -7,145,647
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- By NFLS Delta III Limited
- Underlying class
- Common Stock
- Underlying amount
- 838,886
- Exercise price
- Footnotes
- F1, F6
EVMN
transaction
Derivative
Series Seed Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -3,572,816
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- By Pivotal bioVenture Partners Fund I, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 419,441
- Exercise price
- Footnotes
- F1, F7
EVMN
transaction
Derivative
Series A Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -2,582,243
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- By NFLS Delta III Limited
- Underlying class
- Common Stock
- Underlying amount
- 324,578
- Exercise price
- Footnotes
- F3, F6
EVMN
transaction
Derivative
Series A Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -7,230,283
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- By Pivotal bioVenture Partners Fund I, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 908,821
- Exercise price
- Footnotes
- F3, F7
EVMN
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,895,260
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- By NFLS Delta III Limited
- Underlying class
- Common Stock
- Underlying amount
- 240,756
- Exercise price
- Footnotes
- F4, F6
EVMN
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -2,104,740
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- By Pivotal bioVenture Partners Fund I, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 267,367
- Exercise price
- Footnotes
- F4, F7
EVMN
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -313,571
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- By NFLS Delta III Limited
- Underlying class
- Common Stock
- Underlying amount
- 36,812
- Exercise price
- Footnotes
- F5, F6
EVMN
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -313,571
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- By Pivotal bioVenture Partners Fund I, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 36,812
- Exercise price
- Footnotes
- F5, F7
EVMN
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -2,508,575
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- By Pivotal bioVenture Partners Fund II, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 294,502
- Exercise price
- Footnotes
- F5, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.
Footnote F2
The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
Footnote F3
Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.
Footnote F4
Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.
Footnote F5
Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.
Footnote F6
Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
Footnote F7
Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
Footnote F8
Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.